Rallybio Corporation RLYB
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 646.00K | 858.00K | 858.00K | 674.00K | 761.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 646.00K | 858.00K | 858.00K | 674.00K | 761.00K |
| Cost of Revenue | 9.83M | 15.14M | 19.60M | 21.33M | 25.42M |
| Gross Profit | -9.18M | -14.29M | -18.74M | -20.65M | -24.66M |
| SG&A Expenses | 16.24M | 15.54M | 14.33M | 14.31M | 15.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.07M | 30.68M | 33.92M | 35.63M | 40.86M |
| Operating Income | -25.42M | -29.83M | -33.06M | -34.96M | -40.10M |
| Income Before Tax | 46.88M | -7.82M | -8.98M | -14.17M | -41.65M |
| Income Tax Expenses | 1.32M | -- | -- | -- | -- |
| Earnings from Continuing Operations | 45.55 | -7.82 | -8.98 | -14.17 | -41.65 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 45.55M | -7.82M | -8.98M | -14.17M | -41.65M |
| EBIT | -25.42M | -29.83M | -33.06M | -34.96M | -40.10M |
| EBITDA | -25.38M | -29.76M | -32.97M | -34.84M | -39.99M |
| EPS Basic | 8.02 | -1.37 | -1.60 | -2.55 | -7.45 |
| Normalized Basic EPS | 2.92 | -3.10 | -3.50 | -3.72 | -4.32 |
| EPS Diluted | 7.89 | -1.37 | -1.60 | -2.55 | -7.45 |
| Normalized Diluted EPS | 2.83 | -3.10 | -3.50 | -3.72 | -4.32 |
| Average Basic Shares Outstanding | 22.70M | 22.61M | 22.52M | 22.42M | 22.36M |
| Average Diluted Shares Outstanding | 22.80M | 22.61M | 22.52M | 22.42M | 22.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |